GENETICALLY MODIFIED NK-92 CELLS WITH DECREASED CD96/TIGIT EXPRESSION

1 . A modified NK-92 cell comprising one or more alterations that inhibit expression of one or more target genes, wherein the one or more target genes are selected from the group consisting of CD96 and TIGIT.

2 . The modified NK-92 cell of claim 1 , in which a CD96 gene is genetically altered to inhibit expression of CD96.

3 . The modified NK-92 cell of claim 2 , comprising an interfering RNA that targets CD96 and inhibits expression of CD96.

4 . The modified NK-92 cell of claim 2 , wherein the cell is produced by knocking down or knocking out CD96 expression in the cell.

5 . (canceled)

6 . The modified NK-92 cell of claim 1 , in which a TIGIT gene is genetically altered to inhibit expression of TIGIT.

7 . (canceled)

8 . The modified NK-92 cell of claim 6 , wherein the cell is produced by knocking down or knocking out TIGIT expression in the cell.

9 . (canceled)

10 . The modified NK-92 cell of claim 1 , in which both a CD96 gene is and a TIGIT gene are genetically altered to inhibit expression of TIGIT.

11 . The modified NK-92 cell of claim 10 , wherein the modified NK-92 cells comprises an interfering RNA that targets CD96 and inhibits expression of CD96; and an interfering RNA that targets TIGIT and inhibits expression of TIGIT.

12 . The modified NK-92 cell of claim 10 , wherein the modified NK-92 cell is produced by knocking down or knocking out CD96 expression and knocking down or knocking out TIGIT expression in the cell.

13 . (canceled)

14 . The modified NK-92 cell of claim 1 , wherein the modified NK cell expresses at least one Fc receptor, or at least one chimeric antigen receptor (CAR), or both at least one Fc receptor and at least one CAR on the cell surface.

15 . The modified NK-92 cell of claim 14 , wherein the at least one Fc receptor is CD16 or a CD16 polypeptide is at least 90% identical to amino acids 19-254 of SEQ ID NO:3 and has a valine at position 176, as numbered with reference to SEQ ID NO:13.

16 .- 19 . (canceled)

20 . The modified NK-92 cell of claim 1 , wherein the cell further expresses interleukin-2 targeted to the endoplasmic reticulum.

21 .- 22 . (canceled)

23 . A composition comprising a plurality of modified NK-92 cells of claim 1 .

24 .- 26 . (canceled)

27 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 23 , thereby treating the cancer.

28 . The method of claim 27 , wherein the method further comprising administering an antibody.

29 . (canceled)

30 . A kit for treating cancer, wherein the kit comprises a composition of claim 23 .

31 . A method for producing an NK-92 cell that expresses decreased levels of one or more target genes relative to a control NK-92 cell, the method comprising genetically modifying the expression of the one or more target genes in the NK-92 cell, wherein the one or more target genes are selected from the group consisting of CD96 and TIGIT.

32 .- 33 . (canceled)

34 . The method of claim 31 , wherein the step of genetically modifying the expression of each of the one or more target genes comprises modifying the each of the one or more target genes with a zinc finger nuclease (ZFN), a Tale-effector domain nuclease (TALEN), or a CRIPSR/Cas system.

35 . The method of claim 31 , wherein genetically modifying the expression of each of the one or more target genes comprises:

i) introducing a clustered regularly interspaced short palindromic repeat-associated (Cas) protein into the NK-92 cell and

ii) introducing one or more ribonucleic acids in the NK-92 cell to be modified, wherein the ribonucleic acids direct the Cas protein to hybridize to a target motif of the sequence of the each of the one or more target genes, and wherein the target motif is cleaved.

36 .- 37 . (canceled)

38 . The method of claim 35 , wherein the Cas protein is Cas9.

39 .- 41 . (canceled)

42 . The method of claim 31 , wherein CD96 and TIGIT are both targeted.